Ron Bentsur - Chief Executive Officer and Board Member

Ron Bentsur has served as our Chief Executive Officer as of August 2015 and as a director as of October 2015. Ron Bentsur has more than 15 years of experience in the biotech industry. Until 2015 Mr. Bentsur served for more than five years as the Chief Executive Officer Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), culminating in U.S. Food and Drug Administration approval and year-end 2014 launch of Auryxia™ (ferric citrate). Prior to that Mr. Bentsur served as CEO of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB), a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with Keryx from 2000-2006, serving as the Keryx’s Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr. Bentsur worked as an investment banker in NYC, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA (Magna Cum Laude), from New York University’s Stern Graduate School of Business.

Gil Hakim - President, IL Operations

Gil Hakim has served us as the President of the Israeli operation since August 2015, and was TheraCoat CEO from August 2010 up to the acquisition of Telormedix in August 2015 and the formation of Urogen Pharma. Mr. Hakim has more than 20 years of experience in the biotech industry. Prior to TheraCoat, Mr. Hakim served in recent years as director of new product development at Medispec Ltd., in-charge of new shockwave based product development in various fields as Cardiology, Vascular, Urology and Dermatology. Prior to Medispec, Mr. Hakim was director of Marketing & Clinical Research at MTRE Advanced Technologies Ltd. (a fully owned subsidiary of Mennen Medical Ltd.) that develops thermoregulation devices. Prior to that, he was Business Development Manager at Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI) (acquired by Johnson & Johnson (NYSE: JNJ) in 2008) which develops biological glue & blood derivative products, and before that he served as European Product Manager at Biosense-Webster (Johnson & Johnson (NYSE: JNJ)) in Belgium, following Johnson & Johnson acquisition of Biosense Israel where he was part of the Research and Development team. Mr. Hakim holds a B.Sc. in Life Sciences from Ben-Gurion University, Israel.

Stephen Mullennix - Chief Operating Officer and Interim Chief Financial Officer

Mr. Mullennix is a seasoned executive with deep experience in growth enterprises’ operations and finance, private equity and corporate finance, and the deployment of breakthrough technologies in highly regulated industries. Mr. Mullennix previously served as Chief Financial Officer and Senior Vice President of Operations for SolarReserve, LLC, a global power company that commercialized a breakthrough technology allowing for utility-scale generation and storage of solar power. Prior to SolarReserve, Mr. Mullennix served as a Managing Director at US Renewables Group, a private equity investment fund with more than $750 million of assets under management, Associate Vice President at AECOM Technology Company, and a Co-Founder of Ennix Incorporated, a family wastewater business which serves small municipalities. Mr. Mullennix has been a leader of teams that have won significant awards, including Commercial Application of the Year from Platts Global Energy Awards 2016, Rising Star Company from Platts Global Energy Awards 2015, Acquisition International Business Excellence 2015 Award, and Deloitte Technology Fast 500 2014 #1 Fastest Growing Cleantech Company.

Mark P. Schoenberg, MD - Chief Medical Officer

Mark Schoenberg, MD is an internationally recognized expert in the treatment of urothelial cancer. He received his undergraduate degree from Yale University, his MD from The University of Texas (Houston) and served as a resident in surgery and urology at The Hospital of The University of Pennsylvania. Under the auspices of The American Cancer Society, Dr. Schoenberg completed his fellowship in Urologic Oncology in The James Buchanan Brady Urological Institute of The Johns Hopkins University. Dr. Schoenberg is an active investigator and contributor to the peer-reviewed literature on urologic oncology. He has held prominent roles at several major US universities and served as the Bernard Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins University from 2005-2014. Dr. Schoenberg is a founding member of the scientific advisory board of The Bladder Cancer Advocacy Network.